EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway

Junlong Zhu, Aimin Wang, Hang Tong, Yan Sun, Tinghao Li, Linfeng Wu, Xiaoyu Zhang, Zijia Qin, Weiyang He

Cancers · 24.05.2026 · 18 (11) · 1713

DOI: 10.3390/cancers18111713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 24.05.2026. Verfasst von Junlong Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aberrant glycosylation is closely associated with tumor progression, changes in the tumor microenvironment, and chemoresistance. This study aimed to identify prognostic sialylation-related genes in bladder cancer and define the role of ST3GAL6 in gemcitabine–cisplatin resistance.

Methods

Molecular subtype analysis, prognostic analysis, and risk model construction were performed for sialylation-related genes using transcriptomic data and clinical information from the TCGA database. GC-resistant bladder cancer cell models were established for transcriptomic sequencing and untargeted metabolomic analysis. Cell proliferation and drug sensitivity assays were performed to evaluate the function of ST3GAL6. The regulatory relationship between IGF2BP3, ST3GAL6, and the PI3K pathway was further assessed by combining database analysis with molecular experiments.

Results

Sialylation-related molecular patterns were associated with patient prognosis and tumor microenvironment features, particularly fibroblast-related characteristics, in bladder cancer. The key model gene ST3GAL6 was upregulated in bladder cancer tissues and was closely associated with prognosis. In GC-resistant bladder cancer cells, ST3GAL6 expression was significantly increased and accompanied by enhanced sialylation activity. ST3GAL6 promoted bladder cancer cell proliferation and reduced sensitivity to cisplatin and gemcitabine, at least in part through the PI3K-AKT-mTOR pathway. IGF2BP3 was also upregulated in resistant cells, is positively correlated with ST3GAL6, and may help maintain ST3GAL6’s expression by stabilizing its mRNA.

Conclusions

Our findings suggest that aberrant sialylation is involved in bladder cancer progression and GC resistance. The IGF2BP3-ST3GAL6-PI3K/AKT/mTOR signaling axis may contribute to this process and may serve as a potential biomarker and therapeutic target in bladder cancer.

Schlagwörter

Stichwörter der Autor:innen

PI3K-AKT-mTOR signalingbladder cancergemcitabine–cisplatin resistancemicroenvironmentsialylation

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

Förderung

  • Chongqing Science and Technology Commission

Zitieren

APA

Zhu, J., Wang, A., Tong, H., Sun, Y., Li, T., Wu, L., Zhang, X., Qin, Z., & He, W. (2026). Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway. Cancers, 18(11), 1713. https://doi.org/10.3390/cancers18111713

Vancouver

Zhu J, Wang A, Tong H, Sun Y, Li T, Wu L, et al. Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway. Cancers. 2026;18(11):1713. doi:10.3390/cancers18111713

BibTeX
@article{Zhu2026,
  author = {Zhu, Junlong and Wang, Aimin and Tong, Hang and Sun, Yan and Li, Tinghao and Wu, Linfeng and Zhang, Xiaoyu and Qin, Zijia and He, Weiyang},
  title = {Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1713},
  doi = {10.3390/cancers18111713}
}
Kostenlos starten →